Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.

Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.

Show other versions (1)

<h4>Introduction</h4>Regulatory T cells (Tregs) have attracted attention as a novel therapeutic target to augment the clinical efficacy of immunotherapy. We conducted phase Ia and Ib trials to examine the safety and efficacy of the anti-CCR4 antibody, KW-0761 (mogamulizumab), which may e...

Full description

Bibliographic Details
Main Authors: Kaoru Fujikawa, Takuro Saito, Koji Kurose, Takashi Kojima, Takeru Funakoshi, Eiichi Sato, Kazuhiro Kakimi, Shinsuke Iida, Yuichiro Doki, Mikio Oka, Ryuzo Ueda, Hisashi Wada
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0291772

Internet

https://doi.org/10.1371/journal.pone.0291772

Similar Items